Introduction: 

Peripheral neuropathy (PN) is an insidious disease that is often asymptomatic during the early stages but which can have a significant impact on quality of life at later stages when nerve damage occurs. There is currently no guidance on the use of neurotropic B vitamins (B1, B6, and B12) for the management of asymptomatic and symptomatic PN.

Objective: 

To provide guidance to primary care physicians on an integrated approach to managing PN with neurotropic B vitamins (B1, B6, and B12).

Materials and methods: 

A multidisciplinary panel of eight experts participated in an iterative quasi-anonymous Delphi survey consisting of two rounds of questions and a virtual meeting. A literature review formed the basis of the survey questions. The first round included multiple select, qualitative, and Likert Scale questions; the subsequent round consisted of 2-point scale (agree or disagree) questions that sought to develop consensus-based statements refined from the first round and recommendations derived from discussions during the virtual expert panel meeting.

Results: 

Clinical recommendations for the use of neurotropic B vitamins (B1, B6, and B12) have been developed for the prevention of PN progression or to delay onset in patients at high risk of developing PN. Recommendations have also been provided for the assessment of PN etiology and considerations for the use of loading dose (high dose) and maintenance dose (lower dose) of these neurotropic B vitamins (B1, B6, and B12).

Conclusion: 

These clinical recommendations provide an initial step towards formulating comprehensive guidelines for the early and long-term management of PN with neurotropic B vitamins (B1, B6, and B12) and move beyond addressing only neuropathic pain associated with the late stages of PN.

1. Hakim M, Kurniani N, Pinzon RT, et al. Management of peripheral neuropathy symptoms with a fixed dose combination of high-dose vitamin B1, B6 and B12: A 12-week prospective non-interventional study in Indonesia. Asian J Med Sci 2018;9(1):32–40.
2. Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 2019;19(10):86.
3. Mafukidze AT, Calnan M, Furin J. Peripheral neuropathy in persons with tuberculosis. J Clin Tuberc Other. Mycobact Dis 2016;2:5–11.
4. Zis P, Sarrigiannis P, Rao D, et al. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol 2016;263(10):1903–1910.
5. Malik RA, Andag-Silva A, Dejthevaporn C, et al. Diagnosing peripheral neuropathy in South-East Asia: a focus on diabetic neuropathy. J Diabetes Investig 2020;11(5):1097–1103.
6. Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA 2015;314(20):2172– 2181.
7. Kirthi V, Perumbalath A, Brown E, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ Open Diabetes Res Care 2021;9(1):e002040.
8. Pinzon RT, Renita SRDL. Critical appraisal of neuropathic pain guidelines in Asia. J Med Sci 2019;51(1):73–81.
9. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21(9):976–982.
10. Malik RA, Aldinc E, Chan SP, et al. Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys. Adv Ther 2017;34(6):1426–1437.
11. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113–e88.
12. Baltrusch S. The role of neurotropic B vitamins in nerve regeneration. Biomed Res Int 2021;2021:9968228.
13. Bernetti A, Agostini F, de Sire A, et al. Neuropathic pain and rehabilitation: a systematic review of international guidelines. Diagnostics (Basel) 2021;11(1).
14. Deng Y, Luo L, Hu Y, et al. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol 2016;16:12.
15. National Institue for. Health and Care Excellence (NICE). Neuropathic pain - pharmacological management. 2013; https://www.nice.org.uk/guidance/cg173/evidence/full-guideline-pdf-4840898221. Accessed February 2022, 2022.
16. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136–154.
17. Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 2022;98(1):31–43.
18. Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician 2016;94(3):227–234.
19. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med 2019;20(Suppl 1): S2–S12.
20. Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res 2018;11:1559–1566.
21. Srinivasan A, Paranjothi S, Bhattacharyya K, et al. Consensus recommendations for the management of peripheral neuropathy in India. J Indian Med Assoc 2018;116(10):45–55.
22. Hughes R . Per ipher a l neuropathy. BMJ 2002;324(7335):466–469.
23. Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain 1991;114 ( Pt 5):2175–2190.
24. Schwieger G. Zur Frage der Rezidivprophylaxe von schmerzhaften Wirbelsäulensyndromen durch B-Vitamine. Ergebnisse einer randomisierten Doppelblindstudie Neurobion forte (Vitamin B1, B6, B12) gegen Placebo. In:Zöllner N, Fassl H, Jurna I, Pietrzik K, Schattenkirchner M, eds. Klinische Bedeutung von Vitamin B1, B6, B12 in der Schmerztherapie. Heidelberg: Steinkopff; 1998.
25. Jones MR, Urits I, Wolf J, et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol 2020;15(1):38–48.
26. Anish L, Nagappa M, Mahadevan A, et al. Neuropathy in elderly: lessons learnt from nerve biopsy. Age Ageing 2015;44(2):312–317.
27. Mold JW, Vesely SK, Keyl BA, et al. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004;17(5):309–318.
28. Hashem MM, Esmael A, Nassar AK, et al. The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus. Sci Rep 2021;11(1):1940.
29. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–281.
30. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 2022;45(Suppl 1):S125–S143.
31. Serra MC, Kancherla V, Khakharia A, et al. Longterm metformin treatment and risk of peripheral neuropathy in older veterans. Diabetes Res Clin Pract 2020;170:108486.
32. Shivaprasad C, Gautham K, Ramdas B, et al. Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus. Acta Diabetol 2020;57(9):1073–1080.
33. Arsalan R, Sabzwari S. Isoniazid induced motor-dominant neuropathy. J Pak Med Assoc 2015;65(10):1131–1133.
34. Zaoui A, Abdelghani A, Ben Salem H, et al. Earlyonset severe isoniazid-induced motor-dominant neuropathy: a case report. East Mediterr Health J 2012;18(3):298–299.
35. Aggarwal HK, Sood S, Jain D, et al. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. Ren Fail 2013;35(10):1323–1329.
36. Rizzo G, Laganà AS, Rapisarda AM, et al. Vitamin B12 among Vegetarians: Status, Assessment and Supplementation. Nutrients 2016;8(12).
37. Al Mansoori A, Shakoor H, Ali HI, et al. The effects of bariatric surgery on vitamin B status and mental health. Nutrients 2021;13(4).
38. Riccò M, Rapacchi C, Romboli A, et al. Peripheral neuropathies after bariatric surgery. Preliminary results from a single-centre prospective study in Northern Italy. Acta Biomed 2019;90(3):259–265.
39. Doggrell S. Drug distribution, metabolism and elimination. 2017; https://eprints.qut.edu.au/108464/. Accessed February 2022, 2022.
40. Eussen S, de Groot L, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch I ntern Med 2005;165(10):1167–1172.
41. Abbas ZG, Swai AB. Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East Afr Med J 1997;74(12):803–808.
42. Tong HI. Influence of neurotropic vitamins on the nerve conduction velocity in diabetic neuropathy. Ann Acad Med Singap 1980;9(1):65–70.
43. Langan RC, Goodbred AJ. Vitamin B12 deficiency: Recognition and management. Am Fam Physician 2017;96(6):384–389.
44. Devalia V, Hamilton MS, Molloy AM, et al. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol 2014;166(4):496–513.
45. Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2005;20(3):CD004655.
46. Stein J, Geisel J, Obeid R. Association between neuropathy and B-vitamins: a systematic review and meta-analysis. Eur J Neurol 2021;28(6):2054–2064.
47. Calderon-Ospina CA, Nava-Mesa MO, Paez-Hurtado AM. Update on safety profiles of vitamins B1, B6, and B12: a narrative review. Ther Clin Risk Manag 2020;16:1275–1288.
48. Filipino Neuropathic Pain Technical Committee (FilNeP). Neuropathic pain syndromes. 11th ed: Compendium of Philippine Medicine.
49. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11(4):294–329.
50. Rajan S, Wallace JI, Brodkin KI, et al. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50(11):1789–1795.